Bracco Diagnostics Inc.

Bracco is a global leader in diagnostic imaging established in 1927 in Milan, Italy, with operations in over 100 countries and approximately €2.0 billion in annual revenue. The company operates three main business units: Bracco Imaging, ACIST Medical Systems, and Centro Diagnostico Italiano (CDI). Bracco specializes in contrast agents and imaging solutions for diagnostic radiology, including gadolinium-based contrast agents for MRI, iodamide and iopamidol for X-ray and CT imaging, barium-based products for radiography, and sulfur hexafluoride microbubbles for ultrasound applications. The company manufactures automated injection systems and advanced medical devices for cardiovascular imaging through its ACIST subsidiary, offering solutions in interventional cardiology. Bracco also develops specialized imaging technologies in nuclear oncology and fluorescence image-guided surgery. With 11 innovation centers worldwide and 8% of turnover reinvested in R&D, the company maintains over 2,500 active patents and is recognized for commitment to research, sustainability, and clinical excellence across diagnostic imaging modalities.